IAN G. KERR, M.D.; MARCIA SONE, R.N.; CARLO DeANGELIS, PHARM.D.; NEILL ISCOE, M.D.; ROBERT MacKENZIE, M.D.; TRUDI SCHUELLER, B.Sc., PHARM.D.
Study Objective: To determine the feasibility and safety of outpatient continuous narcotic infusions with additional bolus capabilities (patient-controlled analgesia) in patients with cancer pain.
Design: A single arm (non-randomized) series.
Setting: Outpatient with contact by telephone and through outpatient clinic.
Patients: Consecutive series of 18 patients with poorly controlled cancer pain or significant side effects from regular administration of various narcotics.
Interventions: Patients taught and supervised to use portable pump capable of delivering a continuous narcotic infusion with bolus capabilities.
Measurements and Main Results: All patients had improvement in pain control as judged by the use of a linear analogue scale. Side effects and safety profile were highly acceptable. Narcotics used and maximum doses were meperidine, 50 mg/h; morphine, 80 mg/hr; and hydromorphone, 60 mg/hr. Infusion duration ranged from 7 to 225 days (mean, 54 days).
Conclusions: Continuous narcotic infusions using a programmable portable pump with bolus capabilities is a safe and reliable method of delivering narcotics to outpatients.
KERR IG, SONE M, DeANGELIS C, ISCOE N, MacKENZIE R, SCHUELLER T. Continuous Narcotic Infusion with Patient-Controlled Analgesia for Chronic Cancer Pain in Outpatients. Ann Intern Med. ;108:554–557. doi: 10.7326/0003-4819-108-4-554
Download citation file:
Published: Ann Intern Med. 1988;108(4):554-557.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use